drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
B7-H3 (CD276)–targeted chimeric antigen receptor gamma-delta T cell (CAR-γδ T) therapy; autologous engineered γδ T cells designed to mediate MHC-independent cytotoxicity against B7-H3–expressing solid tumors. Administered as a single infusion with dose escalation (1×10^8–1×10^9 CAR+ γδ T cells).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gamma-delta T cells are engineered to express a chimeric antigen receptor specific for B7-H3 (CD276). Upon binding B7-H3 on tumor cells, CAR signaling activates the γδ T cells to mediate MHC-independent cytotoxicity, leading to tumor cell killing via perforin/granzyme release and cytokine secretion, with expansion and persistence driven by CAR costimulatory/ζ signaling.
drug_name
UTAA06
nct_id_drug_ref
NCT06372236